Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials
Myra Happe(National Institutes of Health), Jamie Sanders(National Institutes of Health), Nancy J. Sullivan(National Institute of Allergy and Infectious Diseases), Pamela Costner(National Institutes of Health), Srilatha Edupuganti(Emory University), Richard A. Koup(National Institutes of Health), Barney S. Graham(National Institutes of Health), Sarah Kabbani(Emory University), Laura Novik(National Institutes of Health), Derick Carr(National Institutes of Health), Zonghui Hu(National Institutes of Health), Emily E. Coates(National Institutes of Health), Mary E. Enama(National Institutes of Health), Brenda Larkin(National Institutes of Health), Nadine Rouphael(Emory University), Susanna Tsukerman(National Institutes of Health), Tamar Murray(National Institutes of Health), Galina V. Yamshchikov(National Institutes of Health), Aurélie Ploquin(National Institutes of Health), Joseph P. Casazza(The University of Texas Southwestern Medical Center), Martin R. Gaudinski(National Institutes of Health), Florence Kaltovich(National Institutes of Health), Julie A. Ake(Walter Reed Army Institute of Research), Ingelise J. Gordon(National Institute of Allergy and Infectious Diseases), Kirsten E. Lyke(University of Maryland, Baltimore), Mark J. Mulligan(New York University), Robert T. Bailer(National Institutes of Health), Hannah Kibuuka(Makerere University Walter Reed Project), John R. Mascola(National Institutes of Health), Katherine V. Houser(National Institutes of Health), Amelia R. Hofstetter(National Institutes of Health), Merlin L. Robb(University of Maryland, Baltimore), Julie E. Ledgerwood(Norwegian Womens Public Health Association), Allan Tindikahwa(Makerere University Walter Reed Project), Colleen F. Kelley(Emory University), Cynthia S. Hendel(National Institutes of Health), Allison Beck, Richard Schwartz(National Institutes of Health), Daphne A. Stanley(National Institutes of Health), Salim Wakabi(Makerere University Walter Reed Project), Grace Chen(National Institutes of Health), Larisa Strom(National Institute of Allergy and Infectious Diseases), Monica Millard(Walter Reed Army Institute of Research), Floreliz Mendoza(National Institutes of Health), Carl Ashman(National Institutes of Health), Fatim Cham(Makerere University Walter Reed Project), Francis Kiweewa(Makerere University Walter Reed Project), Jing Wang(Beijing Institute of Technology), LaSonji A. Holman(National Institutes of Health)
Cited by 19
Related Papers
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Antiretroviral-Drug Resistance among Patients Recently Infected with HIV
|New England Journal of Medicine|2002|1.1k
PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection
|The Journal of Experimental Medicine|2006|874
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
|New England Journal of Medicine|2021|847